PMID- 21722581
OWN - NLM
STAT- MEDLINE
DCOM- 20120325
LR  - 20221207
IS  - 1932-2968 (Electronic)
IS  - 1932-2968 (Linking)
VI  - 5
IP  - 3
DP  - 2011 May 1
TI  - The effect of real-time continuous glucose monitoring on glycemic control in 
      patients with type 2 diabetes mellitus.
PG  - 668-75
AB  - BACKGROUND: Real-time continuous glucose monitoring (RT-CGM) improves hemoglobin 
      A1c (A1C) and hypoglycemia in people with type 1 diabetes mellitus and those with 
      type 2 diabetes mellitus (T2DM) on prandial insulin; however, it has not been 
      tested in people with T2DM not taking prandial insulin. We evaluated the utility 
      of RT-CGM in people with T2DM on a variety of treatment modalities except 
      prandial insulin. METHODS: We conducted a prospective, 52-week, two-arm, 
      randomized trial comparing RT-CGM (n = 50) versus self-monitoring of blood 
      glucose (SMBG) (n = 50) in people with T2DM not taking prandial insulin. 
      Real-time continuous glucose monitoring was used for four 2-week cycles (2 weeks 
      on/1 week off). All patients were managed by their usual provider. This article 
      reports on changes in A1C 0-12 weeks. RESULTS: Mean (+/- standard deviation) 
      decline in A1C at 12 weeks was 1.0% (+/- 1.1%) in the RT-CGM group and 0.5% (+/- 
      0.8%) in the SMBG group (p = .006). There were no group differences in the net 
      change in number or dosage of hypoglycemic medications. Those who used the RT-CGM 
      for >/= 48 days (per protocol) reduced their A1C by 1.2% (+/- 1.1%) versus 0.6% (+/- 
      1.1%) in those who used it <48 days (p = .003). Multiple regression analyses 
      statistically adjusting for baseline A1C, an indicator for usage, and known 
      confounders confirmed the observed differences between treatment groups were 
      robust (p = .009). There was no improvement in weight or blood pressure. 
      CONCLUSIONS: Real-time continuous glucose monitoring significantly improves A1C 
      compared with SMBG in patients with T2DM not taking prandial insulin. This 
      technology might benefit a wider population of people with diabetes than 
      previously thought.
CI  - (c) 2011 Diabetes Technology Society.
FAU - Ehrhardt, Nicole M
AU  - Ehrhardt NM
AD  - Department of Endocrinology and Metabolism, Walter Reed Army Medical Center, 
      Washington DC, USA.
FAU - Chellappa, Mary
AU  - Chellappa M
FAU - Walker, M Susan
AU  - Walker MS
FAU - Fonda, Stephanie J
AU  - Fonda SJ
FAU - Vigersky, Robert A
AU  - Vigersky RA
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20110501
PL  - United States
TA  - J Diabetes Sci Technol
JT  - Journal of diabetes science and technology
JID - 101306166
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Insulin)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Blood Glucose/chemistry
MH  - Blood Glucose Self-Monitoring/*methods
MH  - Diabetes Mellitus, Type 1/*blood/*therapy
MH  - Diabetes Mellitus, Type 2/*blood/*therapy
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemia/drug therapy
MH  - Insulin/metabolism
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Regression Analysis
MH  - Treatment Outcome
PMC - PMC3192632
EDAT- 2011/07/05 06:00
MHDA- 2012/03/27 06:00
PMCR- 2012/05/01
CRDT- 2011/07/05 06:00
PHST- 2011/07/05 06:00 [entrez]
PHST- 2011/07/05 06:00 [pubmed]
PHST- 2012/03/27 06:00 [medline]
PHST- 2012/05/01 00:00 [pmc-release]
AID - dst.5.3.0668 [pii]
AID - 10.1177/193229681100500320 [doi]
PST - epublish
SO  - J Diabetes Sci Technol. 2011 May 1;5(3):668-75. doi: 10.1177/193229681100500320.